Ethnic differences in the distribution of CYP3A5 gene polymorphisms
S Quaranta1, D Chevalier, D Allorge
1Equipe d'Accueil 2679, Facultés de Médecine et de Pharmacie de Lille, Pôle Recherche, Lille, France. sylvie_quaranta@hotmail.com
Xenobiotica; the Fate of Foreign Compounds in Biological Systems
|December 13, 2006
Summary
Genetic variations in the Cytochrome P450 3A5 (CYP3A5) enzyme impact drug metabolism. This study reveals significant interethnic differences in CYP3A5 allele frequencies and expression levels across French, Gabonese, and Tunisian populations.
Area of Science:
- Pharmacogenomics
- Human Genetics
- Enzyme Kinetics
Background:
- Cytochrome P450 3A5 (CYP3A5) enzyme activity exhibits substantial interindividual and interethnic variability.
- This variability influences the metabolism of numerous CYP3A5 substrates, affecting drug efficacy and safety.
- Understanding the genetic basis of this variability is crucial for personalized medicine.
Purpose of the Study:
- To comprehensively analyze the genetic polymorphism of the CYP3A5 enzyme.
- To compare the distribution of CYP3A5 alleles and genotypes across French Caucasian, Gabonese, and Tunisian populations.
- To determine the implications of these genetic differences on CYP3A5 protein expression.
Main Methods:
- Utilized polymerase chain reaction-single strand conformational polymorphism (PCR-SSCP) strategy for genetic analysis.
- Identified single nucleotide polymorphisms (SNPs) and characterized novel allelic variants.
- Quantified allele frequencies and determined genotype distributions within each population.
Main Results:
- Discovered a total of 8, 17, and 10 SNPs in French Caucasian, Gabonese, and Tunisian populations, respectively, including nine novel mutations.
- Identified 16 distinct CYP3A5 alleles, eight of which are newly identified variants.
- Observed significant differences in allele distribution, with the CYP3A5*3C null allele being highly prevalent in French Caucasians (81.3%) and Tunisians (80.0%) compared to Gabonese (12.5%).
- Found that only 10.4% of French Caucasians and 30.0% of Tunisians are CYP3A5 expressors, whereas 90.0% of Gabonese individuals express the CYP3A5 protein.
Conclusions:
- The genetic polymorphism of CYP3A5 significantly varies across ethnic groups, particularly between Europeans/North Africans and Sub-Saharan Africans.
- The high frequency of the CYP3A5*3C null allele in French Caucasian and Tunisian populations leads to a lower proportion of CYP3A5 expressors.
- These findings highlight the importance of considering ethnic background in pharmacogenetic studies involving CYP3A5 substrates to optimize therapeutic outcomes.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...